Last reviewed 2026-05-29 · How we verify

zuojinwan

Nanjing First Hospital, Nanjing Medical University · Phase 1 active Small molecule ✓ Verified May 2026

zuojinwan is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently in Phase 1 development. Also known as: zuojin pills.

Zuojinwan is being studied in combination with Rabeprazole or Mosapride for the treatment of Functional Dyspepsia combined with Depression in a single-centre randomised controlled study. The conditions being studied also include Functional Dyspepsia, Depression, and Gastroesophageal Reflux Disease, with zuojinwan being compared to Rabeprazole sodium enteric-coated tablets and Mosapride citrate.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	zuojinwan
Also known as	zuojin pills
Sponsor	Nanjing First Hospital, Nanjing Medical University
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

zuojinwan CI brief — competitive landscape report
zuojinwan updates RSS · CI watch RSS
Nanjing First Hospital, Nanjing Medical University portfolio CI

Frequently asked questions about zuojinwan

What is zuojinwan?

zuojinwan is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University.

Who makes zuojinwan?

zuojinwan is developed by Nanjing First Hospital, Nanjing Medical University (see full Nanjing First Hospital, Nanjing Medical University pipeline at /company/nanjing-first-hospital-nanjing-medical-university).

Is zuojinwan also known as anything else?

zuojinwan is also known as zuojin pills.

What development phase is zuojinwan in?

zuojinwan is in Phase 1.

Manufacturer: Nanjing First Hospital, Nanjing Medical University — full pipeline
Therapeutic area: All drugs in Other
Also known as: zuojin pills

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing